Androisoxazole
Androisoxazole is an orally active anabolic-androgenic steroid derived from dihydrotestosterone in which an isoxazole ring is fused to the A-ring, structurally analogous to danazol and to the isoxazole-fused compound azolol. It saw limited use in Europe under the brand Neo-Ponden but was never widely studied, so human data are sparse.
01 Overview
Androisoxazole belongs to a small class of A-ring heterocycle-fused androgens that includes danazol and androisoxazole itself. The fused isoxazole confers oral activity and alters receptor binding relative to the parent DHT structure.
Clinical documentation is minimal; the compound is essentially of historical interest and appears in older pharmacological compendia rather than in modern trials. Its side-effect profile is inferred from related oral 17-substituted androgens rather than from dedicated study.
02 Mechanism
Acts as an androgen-receptor agonist; the A-ring isoxazole fusion provides oral bioavailability and non-aromatisable behaviour characteristic of DHT-derived heterocyclic steroids.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Historical | 10–30 mg/day | Oral | Approximate range cited in older European formularies; poorly documented. |
Ester comparison
| Ester | Half-life | Injection freq. | Testosterone by mass |
|---|
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Anabolic / lean tissue supportReported nitrogen-retaining effect typical of oral androgens; not confirmed by controlled trials. | unquantified | Anecdotal | |
| Androgenic supportAndrogen-receptor agonism inferred from structural class. | unquantified | Preclinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| HepatotoxicityLiver strain anticipated from the oral, structurally hindered steroid class. | Moderate | Expected for oral androgens | Preclinical | |
| HPTA suppressionSuppression of endogenous testosterone via androgen feedback. | Moderate | Expected | Preclinical |